Diagnose, Differenzialdiagnose und Diagnostik bei Osteoporose

ZUSAMMENFASSUNG

Die systemische Osteoporose ist gekennzeichnet durch einen Rückgang von Knochenmasse und Knochenstruktur und führt zu einem erhöhten Frakturrisiko. Das Risiko für eine Osteoporose wird beeinflusst vom Lebensalter, dem Geschlecht und weiteren Risikofaktoren. Die rheumatoide Arthritis als chronisch entzündliche Erkrankung der Gelenke führt neben der systemischen Osteoporose zusätzlich zu einer lokalen, periartikulären Osteoporose und auch im fortgeschrittenen Stadium zur Gelenkdestruktion. Daher ist eine möglichst frühe Diagnostik und ggfs. Therapie wichtig. In dem vorliegenden Beitrag sollen die notwendigen Schritte zur Diagnostik und zum Ausschluss von Differenzialdiagnosen aufgezeigt werden. In einem weiteren Beitrag wird die Therapie der Osteoporose geschildert.

SUMMARY

Systemic osteoporosis is characterised by a decrease in bone mass and bone structure and leads to an increased risk of fracture. The risk of osteoporosis is influenced by age, gender and other risk factors. Rheumatoid arthritis as a chronic inflammatory disease of the joints leads, in addition to systemic osteoporosis, to local, periarticular osteoporosis and even in advanced stages to joint destruction. It is therefore important to diagnose and, if necessary, treat the disease as early as possible. The present paper aims to show the necessary steps for diagnosis and exclusion of differential diagnoses. In a further contribution the therapy of osteoporosis will be described.

Schlüsselwörter

Osteoporose - rheumatoide Arthritis - Fraktur - Diagnostik

Keywords

Osteoporosis - rheumatoid arthritis - fracture - diagnostics

Publication History

Article published online:
26 February 2021

• Literatur

• 1 Glaser DL, Kaplan FS. Osteoporosis: definition and clinical presentation. Spine 1997; 22 (24) 12S-126S
• 2 Melton 3 rd LJ, Amin S. Is there a specific fracture ‘cascade’?. Bonekey Rep 2013; 2: 367
• 3 Oberkircher L, Ruchholtz S, Rommens PM. et al Osteoporotic Pelvic Fractures. Dtsch Arztebl Int 2018; 115 (05) 70-80
• 4 Hellmich B. Rheumatoide Arthritis. DoctorConsult – The Journal. Wissen für Klinik und Praxis 2010; 1 (01) 15-21
• 5 Raterman HG, Lems WF. Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide. Drugs Aging 2019; 36 (12) 1061-1972
• 6 Turesson C, O’Fallon WM, Crowson CS. et al Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62 (08) 722-727
• 7 Stach CM, Bäuerle M, Englbrecht M. et al Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum 2010; 62 (02) 330-339
• 8 Kleyer A, Finzel S, Rech J. et al Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 2014; 73 (05) 854-860
• 9 Haugeberg G, Uhlig T, Falch JA. et al Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000; 43 (03) 522-530
• 10 van Staa TP, Geusens P, Bijlsma JW. et al Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54 (10) 3104-3112
• 11 Mohammad A, Lohan D, Bergin D. et al The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis. Rheumatology (Oxford) 2014; 53 (05) 821-827
• 12 Ørstavik RE, Haugeberg G, Mowinckel P. et al Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. Arch Intern Med 2004; 164 (04) 420-425
• 13 Thomasius F, Baum E, Bernecker P. et al DVO Leitlinie 2017 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und Männern. Osteologie 2018; 27 (03) 154-160
• 14 Dennison EM, Compston JE, Flahive J. et al Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 2012; 50 (06) 1288-1293
• 15 Kim SY, Schneeweiss S, Liu J. et al Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 2010; 12 (04) R154
• 16 Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002; 61 (01) 32-36
• 17 Buschhorn-Milberger V, Erkenberg J, Guminski B. et al Evidenz-basierte Prophylaxe, Diagnostik und Therapie der Osteoporose im Jahre 2019. arthritis + rheuma 2019; 39 (06) 375-384
• 18 Carey JJ, Buehring B. Current imaging techniques in osteoporosis. Clin Exp Rheumatol 2018; 36 (Suppl. 114) [phone]
• 19 Buehring B, Thomas J, Wittkämper T. et al [Evaluation of the trabecular bone score (TBS) in routine clinical care of patients with inflammatory rheumatic and non-inflammatory diseases – Correlation with conventional bone mineral density measurement and prevalence of vertebral fractures]. Z Rheumatol 2020; 79 (10) 1067-1074
• 20 Buehring B, Viswanathan R, Binkley N, Busse W. Glucocorticoid-induced osteoporosis: an update on effects and management. J Allergy Clin Immunol 2013; 132 (05) 1019-1030
• 21 Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18 (10) 1319-1328
• 22 Lee YH, Bae SC. Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis. Clin Exp Rheumatol 2016; 34 (05) 827-833